Shannon S. Eaker
42 works · 1,106 citations · h-index 14
Top works
- The Mouse Meiotic Mutation mei1 Disrupts Chromosome Synapsis with Sexually Dimorphic Consequences for Meiotic Progression
- Evidence for meiotic spindle checkpoint from analysis of spermatocytes from Robertsonian-chromosome heterozygous mice
- Meiotic Prophase Abnormalities and Metaphase Cell Death in MLH1-Deficient Mouse Spermatocytes: Insights into Regulation of Spermatogenic Progress
- A consensus introduction to serum replacements and serum-free media for cellular therapies
- Temporal expression of cell cycle-related proteins during spermatogenesis: establishing a timeline for onset of the meiotic divisions
- What are the spermatocyte's requirements for successful meiotic division?
- Multiparameter Flow Cytometry of Fluorescent Protein Reporters
- Concise Review: Guidance in Developing Commercializable Autologous/Patient-Specific Cell Therapy Manufacturing
- Detection and Enrichment of Hematopoietic Stem Cells by Side Population Phenotype
- Bioreactors for cell therapies: Current status and future advances
- Equine peripheral blood‐derived mesenchymal stem cells: Isolation, identification, trilineage differentiation and effect of hyperbaric oxygen treatment
- Regen med therapeutic opportunities for fighting COVID-19
- TLX1/HOX11-induced hematopoietic differentiation blockade
- Improving patient outcomes with regenerative medicine: How the Regenerative Medicine Manufacturing Society plans to move the needle forward in cell manufacturing, standards, 3D bioprinting, artificial intelligence-enabled automation, education, and training
- Shipping and Logistics Considerations for Regenerative Medicine Therapies
- A High-Throughput Antibody-Based Microarray Typing Platform
- Detection of CFTR mutations using ARMS and low-density microarrays
- Artificial intelligence, machine learning, and digitalization systems in the cell and gene therapy sector: a guidance document from the ISCT industry committees
- Bioreactor Technology for Cell Therapy Manufacturing in Regenerative Medicine
- Integrating a 19F MRI Tracer Agent into the Clinical Scale Manufacturing of a T-Cell Immunotherapy